• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    1/3/24 8:05:55 AM ET
    $ABVC
    $AGIO
    $CLDI
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • NexImmune (NASDAQ:NEXI) stock increased by 84.4% to $4.38 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.6 million.
    • ABVC BioPharma (NASDAQ:ABVC) shares moved upwards by 75.0% to $2.1. The company's market cap stands at $16.2 million.
    • First Wave BioPharma (NASDAQ:FWBI) shares increased by 46.07% to $5.58. The market value of their outstanding shares is at $3.7 million.
    • Dyne Therapeutics (NASDAQ:DYN) stock rose 45.4% to $18.99. The company's market cap stands at $1.1 billion.
    • VolitionRX (AMEX:VNRX) shares increased by 19.04% to $1.25. The company's market cap stands at $98.3 million.
    • Agios Pharmaceuticals (NASDAQ:AGIO) shares moved upwards by 18.26% to $27.0. The market value of their outstanding shares is at $1.5 billion.

    Losers

    • Nemaura Medical (NASDAQ:NMRD) shares declined by 20.8% to $0.15 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.3 million.
    • Esperion Therapeutics (NASDAQ:ESPR) stock declined by 18.5% to $2.38. The market value of their outstanding shares is at $270.6 million.
    • Calidi Biotherapeutics (AMEX:CLDI) stock decreased by 9.65% to $1.3. The market value of their outstanding shares is at $46.1 million.
    • SCYNEXIS (NASDAQ:SCYX) stock decreased by 8.6% to $2.02. The market value of their outstanding shares is at $75.1 million.
    • SenesTech (NASDAQ:SNES) stock declined by 8.13% to $1.47. The market value of their outstanding shares is at $1.1 million.
    • NRX Pharmaceuticals (NASDAQ:NRXP) stock declined by 7.8% to $0.46. The market value of their outstanding shares is at $39.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $AGIO
    $CLDI
    $DYN

    CompanyDatePrice TargetRatingAnalyst
    Dyne Therapeutics Inc.
    $DYN
    12/10/2025$40.00Perform → Outperform
    Oppenheimer
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    Agios Pharmaceuticals Inc.
    $AGIO
    11/24/2025Buy
    Truist
    Agios Pharmaceuticals Inc.
    $AGIO
    11/20/2025$34.00Market Perform → Outperform
    Leerink Partners
    Agios Pharmaceuticals Inc.
    $AGIO
    11/19/2025$28.00Outperform → Sector Perform
    RBC Capital Mkts
    Dyne Therapeutics Inc.
    $DYN
    10/10/2025Outperform → Perform
    Oppenheimer
    NRX Pharmaceuticals Inc.
    $NRXP
    9/8/2025$40.00Buy
    H.C. Wainwright
    Dyne Therapeutics Inc.
    $DYN
    8/25/2025$35.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $ABVC
    $AGIO
    $CLDI
    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dyne Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Dyne Therapeutics from Perform to Outperform and set a new price target of $40.00

    12/10/25 8:10:44 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Esperion Therapeutics with a new price target

    Piper Sandler initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $9.00

    11/25/25 8:41:48 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Agios Pharma

    Truist initiated coverage of Agios Pharma with a rating of Buy

    11/24/25 8:30:31 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AGIO
    $CLDI
    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' over-allotment option for gross proceeds of approximately $6.0 million, prior to deducting underwriting commissions and offering expenses. In connection with the offering, the Company sold 12,094,631 shares of common stock (or pre-funded warrants in lieu thereof) Series J warrants to purchase 12,094,631 shares of common stock, Series K warrants to purchase 12,094,63

    3/9/26 8:50:07 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ABVC
    $AGIO
    $CLDI
    $DYN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AGIO
    $CLDI
    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Corp Dev & Strategy Viswanadhan Krishnan sold $82,260 worth of shares (2,959 units at $27.80) and converted options into 8,100 shares (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    3/9/26 4:12:11 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Friedl-Naderer Johanna sold $2,205 worth of shares (148 units at $14.90), decreasing direct ownership by 0.10% to 154,581 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/6/26 4:10:20 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $AGIO
    $CLDI
    $DYN
    SEC Filings

    View All

    SEC Form 10-K filed by Esperion Therapeutics Inc.

    10-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/10/26 4:55:11 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

    3/10/26 7:17:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Calidi Biotherapeutics Inc.

    424B5 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    3/6/26 8:38:07 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $AGIO
    $CLDI
    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Glenbrook Capital Management bought $200,635 worth of shares (85,901 units at $2.34) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/19/26 7:57:41 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Large owner Glenbrook Capital Management bought $56,667 worth of shares (31,346 units at $1.81) (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    2/13/26 5:20:17 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ABVC
    $AGIO
    $CLDI
    $DYN
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer

    Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

    3/2/26 7:00:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Volition Announces the Appointment of New Distributor for Nu.Q® Discover

    HENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme

    2/10/26 8:07:00 AM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABVC
    $AGIO
    $CLDI
    $DYN
    Financials

    Live finance-specific insights

    View All

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Thursday, March 12, 2026

    Financial results to be released after market close; Conference call to be conducted at 5:00 p.m. Eastern timePHOENIX, March 9, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in birth control solutions for managing rodent populations, will report financial results for its fourth quarter and fiscal year 2025, ended December 31, 2025, after the market close on Thursday, March 12, 2026. The Company has scheduled a conference call that same day, Thursday, March 12, 2026, at 5:00 pm ET, to review the results. Fourth Quarter and Fiscal Year 2024 Conference Call DetailsDa

    3/9/26 4:15:00 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

    – Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p

    3/3/26 6:00:00 AM ET
    $ESPR
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $ABVC
    $AGIO
    $CLDI
    $DYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials